Progress toward an elusive goal: current status of cytomegalovirus vaccines

被引:59
作者
Schleiss, Mark R.
Heineman, Thomas C.
机构
[1] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA
[2] Amer Leg Chair Pediat, Minneapolis, MN 55455 USA
[3] St Louis Univ, Sch Med, Div Infect Dis & Immunol, St Louis, MO 63110 USA
关键词
animal models; congenital cytomegalovirus infection; cytomegalovirus; cytomegalovirus immunity; cytomegalovirus in immunocompromised patients; cytomegalovirus vaccines; herpesvirus vaccines;
D O I
10.1586/14760584.4.3.381
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Although infection with human cytomegalovirus (CMV) is ubiquitous and generally asymptomatic in most individuals, certain patient populations are at high risk for CMV-associated disease. These include HIV-infected individuals with AIDS, transplant patients, and newborn infants with congenital CMV infection. Immunity to CMV infection, both in the transplant setting and among women of childbearing age, plays a vital role in the control of CMV-induced injury and disease. Although immunity induced by CMV infection is not completely protective against reinfection, there is nevertheless a sound basis on which to believe that vaccination could help control CMV disease in high-risk patient populations. Evidence from several animal models of CMV infection indicates that a variety of vaccine strategies are capable of inducing immune responses sufficient to protect against CMV-associated illness following viral challenge. Vaccination has also proven effective in improving pregnancy outcomes following CMV challenge of pregnant guinea pigs, providing a 'proof-of-principle' relevant to human clinical trials of CMV vaccines. Although there are no licensed vaccines currently available for human CMV, progress toward this goal has been made, as evidenced by ongoing clinical trial testing of a number of immunization strategies. CMV vaccines currently in various stages of preclinical and clinical testing include: protein subunit vaccines; DNA vaccines; vectored vaccines using viral vectors, such as attenuated pox- and alphaviruses; peptide vaccines; and live attenuated vaccines. This review summarizes some of the obstacles that must be overcome in development of a CMV vaccine, and provides an overview of the current state of preclinical and clinical trial evaluation of vaccines for this important public health problem.
引用
收藏
页码:381 / 406
页数:26
相关论文
共 227 条
  • [91] REDUCED CONGENITAL CYTOMEGALOVIRUS (CMV) INFECTION AFTER MATERNAL IMMUNIZATION WITH A GUINEA-PIG CMV GLYCOPROTEIN BEFORE GESTATIONAL PRIMARY CMV INFECTION IN THE GUINEA-PIG MODEL
    HARRISON, CJ
    BRITT, WJ
    CHAPMAN, NM
    MULLICAN, J
    TRACY, S
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (05) : 1212 - 1220
  • [92] HEINEMAN T, 2002, 27 HERP SIMPL VIR WO
  • [93] Huang E S, 1980, Ann N Y Acad Sci, V354, P332, DOI 10.1111/j.1749-6632.1980.tb27976.x
  • [94] ISOLATION AND CHARACTERIZATION OF A NON-INFECTIOUS VIRION-LIKE PARTICLE RELEASED FROM CELLS INFECTED WITH HUMAN STRAINS OF CYTOMEGALOVIRUS
    IRMIERE, A
    GIBSON, W
    [J]. VIROLOGY, 1983, 130 (01) : 118 - 133
  • [95] Just M, 1975, Infection, V3, P111, DOI 10.1007/BF01641052
  • [96] ANALYSIS OF HUMAN-ANTIBODY RESPONSES TO HUMAN CYTOMEGALOVIRUS ENVELOPE GLYCOPROTEINS FOUND IN 2 FAMILIES OF DISULFIDE LINKED GLYCOPROTEIN COMPLEXES DESIGNATED GC-I AND GC-II
    KARI, B
    GEHRZ, R
    [J]. ARCHIVES OF VIROLOGY, 1990, 114 (3-4) : 213 - 228
  • [97] Defined large-scale alteration of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids
    Kemble, G
    Duke, G
    Winter, R
    Spaete, R
    [J]. JOURNAL OF VIROLOGY, 1996, 70 (03) : 2044 - 2048
  • [98] Target structures of the CD8+-T-cell response to human cytomegalovirus:: the 72-kilodalton major immediate-early protein revisited
    Kern, F
    Surel, IP
    Faulhaber, N
    Frömmel, C
    Schneider-Mergener, J
    Schönemann, C
    Reinke, P
    Volk, HD
    [J]. JOURNAL OF VIROLOGY, 1999, 73 (10) : 8179 - 8184
  • [99] Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals
    Kern, F
    Bunde, T
    Faulhaber, N
    Kiecker, F
    Khatamzas, E
    Rudawski, IM
    Pruss, A
    Gratama, JW
    Volkmer-Engert, R
    Ewert, R
    Reinke, P
    Volk, HD
    Picker, LJ
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (12) : 1709 - 1716
  • [100] Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system:: A randomized, controlled trial
    Kimberlin, DW
    Lin, CY
    Sánchez, PJ
    Demmler, GJ
    Dankner, W
    Shelton, M
    Jacobs, RF
    Vaudry, W
    Pass, RF
    Kiell, JM
    Soong, SJ
    Whitley, RJ
    [J]. JOURNAL OF PEDIATRICS, 2003, 143 (01) : 16 - 25